Aurinia Pharmaceuticals AUPH
NASDAQ AUPH
$16.08 -0.04 (-0.25%)
As of: Sep 4, 2026 · 3:59 PM EDT

Aurinia Pharmaceuticals (AUPH) Change in Acquisitions & Divestments (2020 - 2026)

Aurinia Pharmaceuticals' (AUPH) quarterly Change in Acquisitions & Divestments came in at $109.0 million in Q1 2026, down 11.41% YoY from $123.0 million in Q1 2025, and down 25.01% on a QoQ basis from $145.3 million in Q4 2025.

Analysis

Aurinia Pharmaceuticals (AUPH) Change in Acquisitions & Divestments (2020 - 2026) Analysis & Trends

Aurinia Pharmaceuticals (AUPH) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $109.0 million in Q1 2026.

  • Quarterly Change in Acquisitions & Divestments fell 11.41% year-over-year to $109.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $480.1 million (down 10.75% YoY) and the FY2025 annual result came in at $494.1 million, down 15.59% from the prior year.
  • Change in Acquisitions & Divestments fell to $109.0 million in Q1 2026, from $145.3 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $170.5 million in Q1 2024 to a low of $93.5 million in Q3 2025.
  • A 5-year average of $128.4 million and a median of $123.0 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
  • Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments jumped 81.43% — and 2025, when it dropped 29.47%.
  • Tracing AUPH's Change in Acquisitions & Divestments over 5 years: stood at $118.2 million in 2022, then rose by 16.82% to $138.1 million in 2023, then dropped by 10.22% to $124.0 million in 2024, then increased by 17.25% to $145.3 million in 2025, then declined by 25.01% to $109.0 million in 2026.
  • The last three Change in Acquisitions & Divestments figures came in at $109.0 million (Q1 2026), $145.3 million (Q4 2025), and $93.5 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Aurinia Pharmaceuticals 2.10 Bn 1.66 Bn 76.67 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 100.00 Mn
Mar 31, 2026 109.00 Mn
Dec 31, 2025 145.35 Mn
Sep 30, 2025 93.50 Mn
Jun 30, 2025 132.25 Mn
Mar 31, 2025 123.04 Mn
Dec 31, 2024 123.97 Mn
Sep 30, 2024 132.57 Mn
Jun 30, 2024 158.37 Mn
Mar 31, 2024 170.51 Mn
Dec 31, 2023 138.09 Mn
Sep 30, 2023 103.00 Mn
Jun 30, 2023 120.53 Mn
Mar 31, 2023 167.77 Mn
Dec 31, 2022 118.21 Mn
Sep 30, 2022 120.43 Mn
Jun 30, 2022 115.11 Mn
Mar 31, 2022 110.57 Mn
Dec 31, 2021 90.68 Mn
Sep 30, 2021 99.10 Mn